Reason for request

Renouvellement d'inscription

-


Clinical Benefit

Moderate

The actual benefit of OMNITROPE in adults with GH deficiency remains moderate.

Low

The actual benefit of OMNITROPE in children born small for gestational age with a birth weight and/or length < -2 SD, who have failed to show catch-up growth (growth velocity < 0 SD during the last year) by 4 years of age or later and whose growth retardation (current height) is below or equal to -3 SD and the adjusted parental height < -1 SD remains low.

Substantial

The actual benefit of OMNITROPE in children with GH deficiency remains substantial.

The actual benefit of OMNITROPE in Turner syndrome remains substantial.

The actual benefit of OMNITROPE in chronic renal impairment remains substantial.


Contact Us

Évaluation des médicaments

See also